MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414168 | Name: Evogliptin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Evogliptin Free Base is a dipeptidyl peptidase IV inhibitor.

Chemical Structure

Evogliptin Free Base
Evogliptin Free Base
CAS#1222102-29-5 (free base)

Theoretical Analysis

MedKoo Cat#: 414168

Name: Evogliptin Free Base

CAS#: 1222102-29-5 (free base)

Chemical Formula: C19H26F3N3O3

Exact Mass: 401.1926

Molecular Weight: 401.43

Elemental Analysis: C, 56.85; H, 6.53; F, 14.20; N, 10.47; O, 11.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1222102-29-5 (free base) 1246960-27-9 (HCl)
Synonym
Evogliptin Free Base; DA1229; DA 1229; DA-1229
IUPAC/Chemical Name
(R)-4-((R)-3-Amino-4-(2,4,5-trifluorophenyl)-butanoyl)-3-(t-butoxymethyl)-piperazin-2-one
InChi Key
LCDDAGSJHKEABN-MLGOLLRUSA-N
InChi Code
InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
SMILES Code
O=C1NCCN(C(C[C@H](N)CC2=CC(F)=C(F)C=C2F)=O)[C@@H]1COC(C)(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 401.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kim G, Lim S, Kwon HS, Park IB, Ahn KJ, Park CY, Kwon SK, Kim HS, Park SW, Kim SG, Moon MK, Kim ES, Chung CH, Park KS, Kim M, Chung DJ, Lee CB, Kim TH, Lee MK. Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study). Diabetes Obes Metab. 2020 Sep;22(9):1527-1536. doi: 10.1111/dom.14061. Epub 2020 May 29. PMID: 32319168; PMCID: PMC7496811. 2: Ba YD, Sun JH, Zhao XX. Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-β/Smad signaling in fibroblast. Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10790-10798. doi: 10.26355/eurrev_202010_23439. PMID: 33155239. 3: Hong T, Jin BH, Kim CO, Yoo BW, Kim D, Lee JI, Kim BK, Ahn SH, Kim DY, Park JY, Park MS. Pharmacokinetics and safety of evogliptin in hepatically impaired patients. Br J Clin Pharmacol. 2020 Nov 27. doi: 10.1111/bcp.14680. Epub ahead of print. PMID: 33245796. 4: Tan X, Hu J. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2016 Jun;17(9):1285-93. doi: 10.1080/14656566.2016.1183645. Epub 2016 May 13. PMID: 27156529. 5: Kim MJ, Kim NY, Jung YA, Lee S, Jung GS, Kim JG, Lee IK, Lee S, Choi YK, Park KG. Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice. Diabetes Metab J. 2020 Feb;44(1):186-192. doi: 10.4093/dmj.2018.0271. Epub 2019 Oct 31. PMID: 31701692; PMCID: PMC7043988. 6: Yoo H, Kim Y, Jang IJ, Yu KS, Lee S. Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects. Drug Des Devel Ther. 2020 Nov 24;14:5179-5187. doi: 10.2147/DDDT.S275343. PMID: 33262578; PMCID: PMC7699451. 7: Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S. Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects. Drug Des Devel Ther. 2020 Oct 23;14:4493-4502. doi: 10.2147/DDDT.S275336. PMID: 33122892; PMCID: PMC7591087. 8: Seo S, Kim MK, Kim RI, Yeo Y, Kim KL, Suh W. Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation. Exp Mol Med. 2020 Oct;52(10):1744-1753. doi: 10.1038/s12276-020-00512-8. Epub 2020 Oct 14. PMID: 33051573; PMCID: PMC8080693. 9: Lee DY, Kim JH, Shim HJ, Jeong HU, Lee HS. Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. J Toxicol Environ Health A. 2018;81(11):453-464. doi: 10.1080/15287394.2018.1451194. Epub 2018 Mar 20. PMID: 29557727. 10: Kim JH, Jang SJ, Roh GS, Cho HS, Kang H, Kim SK. Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice. Int J Mol Sci. 2020 Sep 14;21(18):6743. doi: 10.3390/ijms21186743. PMID: 32937958; PMCID: PMC7555947.

View History

DC661

DC661

New Featured